Healthcare Web Wire

Author: Elena Morales

  • Musculoskeletal Disorders Treatment Market Trends, Growth and Future Outlook

    Musculoskeletal Disorders Treatment Market Trends, Growth and Future Outlook

    Musculoskeletal Disorders Treatment Market Growth and Insights

    The global musculoskeletal disorders treatment market was valued at USD 186.02 billion in 2023 and is anticipated to grow to USD 326.26 billion by 2032. This growth reflects a compound annual growth rate (CAGR) of 6.0% from 2024 to 2032.

    Musculoskeletal Disorders Treatment Market Size 2023 - 2032

    Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5148

    Key Findings:

    • Osteoarthritis led the market, holding a 33% share in 2023.
    • Medications dominated the treatment segment, accounting for over 60% of the market in 2023.
    • North America was the largest regional market, with a 37% share in 2023.
    • On March 3, 2024, Goa Medical College introduced India’s first coated knee implants, priced under Rs. 1 lakh (around Rs. 80,000). The implants are expected to last 30 years, compared to the typical 15-20 years of standard implants, which usually cost about Rs. 60,000.

    Musculoskeletal disorders refer to conditions that affect the muscles, bones, tendons, ligaments, and nerves, often causing pain, stiffness, swelling, and reduced mobility. Common examples include arthritis, tendonitis, carpal tunnel syndrome, and back pain.

    Early detection of musculoskeletal disorders is essential for several reasons. It enables timely treatment, preventing the condition from worsening and helping to relieve symptoms. Early intervention can also protect the affected tissues from further damage, improving the long-term outlook and reducing the risk of complications.

    Trends in the Musculoskeletal Disorders Treatment Market

    1. Increased Demand for Non-Surgical Treatments: There is a growing preference for non-invasive treatments, such as physical therapy, medication, and injections (e.g., corticosteroids, hyaluronic acid), as patients seek alternatives to surgery for managing musculoskeletal disorders.
    2. Rise in Personalized Medicine: Advancements in genetic research and technology have led to a rise in personalized treatments tailored to an individual’s specific needs, offering better outcomes and reducing side effects.
    3. Growing Use of Biologic Treatments: The adoption of biologics, including stem cell therapies and platelet-rich plasma (PRP) treatments, is on the rise. These therapies are gaining popularity for their potential to promote tissue repair and reduce inflammation.
    4. Technological Innovations: The use of advanced technologies such as robotics, artificial intelligence (AI), and 3D printing is enhancing surgical outcomes and the development of customized implants, particularly for conditions like osteoarthritis.
    5. Focus on Minimally Invasive Procedures: There is a shift towards minimally invasive surgeries, which offer quicker recovery times, reduced risks of complications, and less pain for patients compared to traditional open surgeries.
    6. Expansion of Knee and Hip Implant Market: The demand for joint replacement surgeries, particularly knee and hip implants, is increasing due to the aging population and rising incidences of osteoarthritis, one of the most common musculoskeletal conditions.
    7. Growing Awareness and Early Diagnosis: Public awareness campaigns and improved diagnostic tools are encouraging earlier detection and treatment of musculoskeletal disorders, leading to better patient outcomes.
    8. Aging Population and Lifestyle Factors: The aging global population, along with increasing sedentary lifestyles, is contributing to a rise in musculoskeletal disorders, especially arthritis and back pain, driving demand for treatment options.
    9. Integration of Telemedicine: The incorporation of telemedicine into musculoskeletal care is making treatment more accessible, allowing patients to receive consultations and follow-ups remotely, improving patient engagement and convenience.
    10. Focus on Patient-Centric Care: There is a growing emphasis on providing holistic, patient-centered care, focusing not only on the physical aspects of treatment but also on emotional support and rehabilitation, contributing to better overall outcomes.

    Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions:  https://www.towardshealthcare.com/table-of-content/musculoskeletal-disorders-treatment-market-sizing

    Access exclusive insight now @ https://www.towardshealthcare.com/price/5148

    We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

    Web: https://www.towardshealthcare.com

    Visit Dental Specifics: https://www.towardsdental.com

    Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

    For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

  • Antipsychotic Drugs Market Key Players and Industry Insights

    Antipsychotic Drugs Market Key Players and Industry Insights

    Opportunities and Growth in the Antipsychotic Drugs Market

    The global market for antipsychotic drugs was valued at approximately USD 18.04 billion in 2023 and is expected to reach about USD 37.40 billion by 2032. This represents a compound annual growth rate (CAGR) of 7.8% from 2024 to 2032.

    Antipsychotic Drugs Market Size 2023 - 2032

    Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5147

    Key Findings:

    • In 2023, second-generation antipsychotic drugs held the largest share of the market, accounting for 65%.
    • Schizophrenia was the most common condition treated with antipsychotic drugs, representing 52% of the market in 2023.
    • North America was the leading region in the antipsychotic drugs market, holding a 37% share in 2023.

    Key Companies in the Antipsychotic Drugs Market

    • Otsuka Holdings Co., Ltd. (Otsuka Pharmaceutical Co., Ltd.): A global leader in healthcare, Otsuka is known for developing innovative antipsychotic medications, including the popular drug, Abilify, used to treat conditions like schizophrenia and bipolar disorder.
    • Teva Pharmaceutical Industries Ltd.: As one of the largest generic drug manufacturers, Teva also produces antipsychotic treatments such as Quetiapine (Seroquel), which is widely used to manage schizophrenia and other mental health conditions.
    • Eli Lilly and Company: Known for its breakthrough drugs, Eli Lilly is a key player in the antipsychotic drugs market, with medications like Zyprexa for schizophrenia and bipolar disorder.
    • Dr. Reddy’s Laboratories Limited: A prominent global pharmaceutical company, Dr. Reddy’s manufactures a wide range of generic antipsychotic drugs, providing affordable treatment options for patients worldwide.
    • AstraZeneca PLC: This multinational pharmaceutical company offers antipsychotic medications such as Seroquel, a treatment for schizophrenia, depression, and bipolar disorder.
    • Johnson & Johnson (Janssen Pharmaceuticals): A leader in the pharmaceutical industry, Janssen, a subsidiary of Johnson & Johnson, markets the widely used antipsychotic drug Risperdal, which is used to treat various mental health conditions.
    • Pfizer Inc.: Pfizer is a global pharmaceutical giant with a strong portfolio of medications, including antipsychotic drugs like Geodon, used to treat schizophrenia and bipolar disorder.
    • Alkermes Plc.: Specializing in central nervous system treatments, Alkermes develops innovative drugs like Vivitrol, which helps manage schizophrenia and other psychiatric disorders.
    • AbbVie Inc. (Allergan Inc.): AbbVie, following its acquisition of Allergan, offers a range of psychiatric treatments, including antipsychotics like the injectable medication, Vraylar, for managing schizophrenia and bipolar disorder.
    • Bristol-Myers Squibb: This leading biopharmaceutical company is involved in the development of antipsychotic medications, including those for the treatment of schizophrenia and related disorders.

    Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/antipsychotic-drugs-market-sizing

    Access exclusive insight now @ https://www.towardshealthcare.com/price/5147

    We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

    Web: https://www.towardshealthcare.com

    Visit Dental Specifics: https://www.towardsdental.com

    Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

    For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

  • Liver Cancer Drugs Market Growth and Innovations

    Liver Cancer Drugs Market Growth and Innovations

    Liver Cancer Drugs Market Growth and Recent Advancements

    In 2023, the liver cancer drugs market was valued at $2.67 billion. By 2032, it is expected to grow significantly, reaching $9.94 billion with an impressive compound annual growth rate (CAGR) of 14.2% from 2024 to 2032.

    Liver Cancer Drugs Market Size 2023 - 2032

    Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5146

    Report Highlights

    • Targeted therapies made up the largest portion of the market in 2022, accounting for 52% of the total share.
    • Hospital pharmacies dominated distribution channels, capturing a significant 71% of the market share in 2022.
    • North America emerged as the leading region, holding 34% of the market share in 2022.

    CSIR’s Breakthrough in Liver Cancer Research – January 2024

    The Central Drug Research Institute (CDRI), India, has made significant progress in liver cancer research through a collaborative study. The research focuses on the metabolic changes occurring in cells that could play a key role in preventing hepatocellular carcinoma (HCC), the most common type of liver cancer.

    Conducted in partnership with CIMAP, CBMR, and CSIR-CDRI, the study highlights how cancer cells undergo a shift in metabolic programming. These alterations could pave the way for improved diagnostic and preventive strategies.

    Led by Dr. Madhav Nilakanth Mugale of CSIR-CDRI, the research used an animal model to replicate the progression of HCC in humans. It identified critical changes associated with disease advancement, such as decreased body mass, elevated serum enzyme levels, and alterations in liver structure.

    Published in the prestigious Elsevier journal, this study opens the door to developing targeted therapies based on metabolic reprogramming, offering hope for more effective treatments for liver cancer.

    Liver Cancer Drugs Market Companies

    Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/liver-cancer-drugs-market-sizing

    Access exclusive insight now @ https://www.towardshealthcare.com/price/5146

    We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

    Web: https://www.towardshealthcare.com

    Visit Dental Specifics: https://www.towardsdental.com

    Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

    For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

     

  • Anxiety Disorders Treatment Market Size, Trends and Key Players Analysis

    Exploring the Future of Anxiety Disorder Treatments Market Trends and Growth Insights

    The market for anxiety disorder treatments was valued at USD 11.49 billion in 2023 and is expected to grow significantly, reaching an estimated USD 15.90 billion by 2032. This growth reflects a steady compound annual growth rate (CAGR) of 3.6% from 2024 to 2032.

    Anxiety Disorders Treatment Market Size 2023 - 2032

    Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5145

    Key Insights from the Report:

    • Generalized Anxiety Disorder accounted for the largest portion of the market, capturing 34% of the share in 2022.
    • Selective Serotonin Reuptake Inhibitors (SSRIs) emerged as the leading drug class, holding a 32% market share in 2022.
    • Hospital outpatient settings dominated treatment delivery, commanding an impressive 71% of the market share in 2022.

    Rising Awareness of Mental Health and Its Impact on Anxiety Disorder Treatments

    As awareness of mental health issues grows, more people are recognizing the importance of seeking help for conditions like anxiety disorders. In the past, stigma and shame often prevented individuals from admitting they needed support. Today, this is changing as open conversations about mental health become more common. These discussions help individuals feel less isolated and more encouraged to seek treatment.

    This cultural shift is fostering a more accepting environment where people acknowledge anxiety as a legitimate health concern. As judgment and embarrassment diminish, individuals are increasingly reaching out for professional support. This support might involve therapy, medication, or exploring other treatment options. As more people take these steps, the demand for anxiety disorder treatments continues to rise.

    The ripple effect is profound—when one person shares their story, it inspires others to do the same. This growing awareness fosters understanding that anxiety is a widespread condition that deserves attention and care, just like any other health issue.

    On a broader scale, mental health initiatives are gaining traction. For example, between 2015 and 2020, approximately 76,000 mental health grants were issued by 345 organizations across 38 countries, amounting to around $18.5 billion in funding. However, most of these investments (89%) were directed to high-income countries, with the United States alone contributing 39% of all grants.

    Additionally, advancements in treatments continue to emerge. In December 2020, H. Lundbeck A/S’s Marketing Authorization Application (MAA) for Vyepti was accepted for review by the European Medicines Agency (EMA). Vyepti, aimed at preventing migraines by blocking calcitonin gene-related peptide (CGRP) interactions, exemplifies the progress being made in addressing related neurological conditions.

    As mental health awareness grows, so does the commitment to ensuring that individuals can access the treatment and support they need. This shift is paving the way for a future where mental health is prioritized, and more people can lead happier, healthier lives.

    Key Companies in the Anxiety Disorders Treatment Market

    The anxiety disorders treatment market features several prominent players, including:

    • Pfizer Inc.
    • Merck KGaA
    • Sanofi
    • Bristol-Myers Squibb Company
    • Eli Lilly
    • Teva Pharmaceutical Industries
    • Bayer AG
    • Biocare Medical, LLC
    • GSK plc.
    • Mitsubishi Chemical Group Corporation

    Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/anxiety-disorders-treatment-market-sizing

    Access exclusive insight now @ https://www.towardshealthcare.com/price/5145

    We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

    Web: https://www.towardshealthcare.com

    Visit Dental Specifics: https://www.towardsdental.com

    Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

    For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

  • Epilepsy Drugs Market Growth, Key Trends and Insights (2024 – 2032)

    Epilepsy Medication Market Growth, Key Players and Trends (2024 – 2032)

    The global market for epilepsy medications was valued at USD 9.50 billion in 2023 and is expected to grow to USD 15.16 billion by 2032. This growth reflects a compound annual growth rate (CAGR) of 5.1% from 2024 to 2032.

    Epilepsy Drugs Market Size 2023 - 2032

    Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5144

    Report Highlights:

    • Third-generation anti-epileptic drugs were the top revenue generators in 2022, accounting for 37% of the market share.
    • Hospital pharmacies made up the largest share of the market in 2022, holding 46%.
    • North America led the epilepsy medication market in 2022, with a 38% market share.
    • As of February 2024, the World Health Organization estimates that about 50 million people in the U.S. have epilepsy, and they face an increased risk of premature death.

    About Epilepsy:

    Epilepsy is a neurological condition characterized by recurring seizures, which occur when there are sudden bursts of electrical activity in the brain that disrupt its normal function. The symptoms of epilepsy can vary widely between individuals, ranging from mild to severe. Seizures may include convulsions, muscle spasms, loss of consciousness, or unusual movements. Some individuals may experience blank staring or other psychic symptoms like fear or déjà vu before a seizure. After a seizure, people might feel confused, forgetful, or have difficulty speaking.

    Treating epilepsy is vital for improving the quality of life of those affected by the condition. Effective treatment aims to reduce the frequency and severity of seizures, making everyday tasks safer and preventing accidents, such as those that can occur while driving or swimming.

    Epilepsy can be thought of as an “electrical storm” in the brain, where unexpected bursts of electrical signals cause seizures. These seizures can take different forms, such as uncontrollable muscle jerks or moments of blank staring, which can feel like a brief disconnection from the surroundings.

    Epilepsy Drugs Market Companies

    • Sanofi
    • Pfizer, Inc.
    • UCB S.A
    • Belgium
    • Otsuka America Pharmaceutical, Inc.
    • Novartis AG
    • GlaxoSmithKline plc.
    • Abbott Laboratories, Inc.
    • Neurelis Inc.
    • Jazz Pharmaceuticals plc.

    Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/epilepsy-drugs-market-sizing

    Access exclusive insight now @ https://www.towardshealthcare.com/price/5144

    We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

    Web: https://www.towardshealthcare.com

    Visit Dental Specifics: https://www.towardsdental.com

    Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

    For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

  • Key Players in the Spinal Cord Injury Treatment Market

    Key Players in the Spinal Cord Injury Treatment Market

    Growth and Forecast of the Spinal Cord Injury Treatment Market

    The spinal cord injury treatment market was valued at USD 7.13 billion in 2023 and is expected to grow to USD 11.00 billion by 2032. This growth is projected at a compound annual growth rate (CAGR) of 4.8% from 2024 to 2032.

    Spinal Cord Injury Treatment Market Size 2023 - 2032

    Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5143

    Report Highlights:

    • Complete spinal cord injuries held the largest market share in 2023, accounting for 60%.
    • Corticosteroids made up 40% of the market share in 2023.
    • Hospitals were the leading contributors to the market, holding 60% of the share in 2023.
    • Every year, approximately 18,000 new spinal cord injuries are reported in the United States, based on an annual incidence rate of 54 cases per million people. The high number of individuals living with spinal cord injuries underscores the ongoing need for prevention and treatment efforts.

    A spinal cord injury occurs when the bundle of nerves in the spine is damaged, which can lead to changes in sensation, movement, and strength below the injury site. This injury can result from direct trauma or damage to the bones around the spine. Symptoms vary depending on the severity and location of the injury. Injuries higher up on the spine can affect larger areas of the body, potentially causing paralysis, while injuries lower on the spine may only affect the legs.

    Common symptoms of spinal cord injuries include numbness, tingling, or loss of sensation in the hands and feet, as well as paralysis, pain, or pressure in the head, neck, or back. Other symptoms may include weakness, difficulty walking, breathing problems, and changes in sexual function. In the U.S., motor vehicle accidents and serious falls are the leading causes of spinal cord injuries, followed by violence, sports injuries, medical accidents, and other incidents. Age, alcohol use, certain medical conditions, and failure to use appropriate safety measures like seat belts or sports equipment can increase the risk of spinal cord injury.

    Older individuals are more prone to spinal cord injuries due to age-related changes in the spine, such as degenerative disc disease. With the global population aging, the incidence of spinal cord injuries is expected to rise, emphasizing the growing need for spinal implants and devices.

    According to the National Spinal Cord Injury Association, about 282,000 people in the U.S. are living with spinal cord injuries, and around 17,000 new cases are diagnosed annually. These numbers highlight the increasing demand for specialized treatments and interventions to support individuals with spinal cord injuries.

    Companies in the Spinal Cord Injury Treatment Market

    • Acorda Therapeutics, Inc.
    • Asterias Biotherapeutics
    • ReNetX Bio
    • BioArctic AB
    • BioTime, Inc.
    • InVivo Therapeutics
    • Kringle Pharma, Inc.
    • Novartis AG
    • Pfizer Inc.
    • Pharmicell Co. Ltd.

    Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/spinal-cord-injury-treatment-market-sizing

    Access exclusive insight now @ https://www.towardshealthcare.com/price/5143

    We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

    Web: https://www.towardshealthcare.com

    Visit Dental Specifics: https://www.towardsdental.com

    Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

    For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

     

  • Fibromyalgia Treatment Market Overview (2024 – 2032)

    Fibromyalgia Treatment Market Growth, Trends and Key Players (2024 – 2032)

    The global fibromyalgia treatment market is projected to expand from USD 2.77 billion in 2023 to approximately USD 4.13 billion by 2032, growing at a compound annual growth rate (CAGR) of 4.3% from 2024 to 2032.

    Fibromyalgia Treatment Market Size 2023 - 2032

    Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5139 

    Report Highlights:

    • Ongoing development of new and innovative treatment options for fibromyalgia.
    • Increasing demand for fibromyalgia treatments driving market growth.
    • Medications held the largest market share at 68% in 2023.
    • Retail pharmacies were the leading distributors, capturing 54% of the market share in 2023.
    • North America was the largest market contributor, accounting for 40% of the global share in 2023.

    Fibromyalgia affects around 4 million adults in the United States, roughly 2% of the adult population. While the exact cause remains unknown, effective treatment options are available. As the need for these treatments grows, researchers are exploring new approaches beyond traditional medications.

    Fibromyalgia is characterized by widespread muscle pain, fatigue, difficulty concentrating, and other emotional and physical symptoms. Although people with fibromyalgia experience pain in muscles and soft tissues, there is no visible inflammation in these areas.

    Research suggests that fibromyalgia may be linked to how the body processes pain, a condition known as central sensitization syndrome. It is more common in women, with approximately 6.4% of the U.S. population affected (7.7% in women and 4.9% in men). Studies in Europe and South America show similar rates, ranging from 3.3% to 8.3%. Fibromyalgia is more prevalent as people age, often affecting women between the ages of 20 and 55. Teenagers can also experience fibromyalgia at similar rates as adults, and in specialized pain clinics, over 40% of patients meet the criteria for the condition.

    Fibromyalgia Treatment Market Companies

    • Eli Lilly and Company
    • Pfizer Inc.
    • AbbVie Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Merck & Co., Inc.
    • Sun Pharmaceuticals Industries Ltd.
    • Novartis AG
    • Astellas Pharma Inc.
    • Aptinyx Inc.

    Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/fibromyalgia-treatment-market-sizing

    Access exclusive insight now @ https://www.towardshealthcare.com/price/5139

    We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

    Web: https://www.towardshealthcare.com

    Visit Dental Specifics: https://www.towardsdental.com

    Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

    For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

  • Osteoarthritis Market Analysis Key Trends, Drivers and Growth Forecast (2024 – 2032)

    Osteoarthritis Market Growth, Trends, and Key Companies (2024 – 2032)

    The osteoarthritis market is expected to grow significantly, from USD 8.60 billion in 2023 to approximately USD 19.15 billion by 2032, reflecting a compound annual growth rate (CAGR) of 8.4% during the forecast period from 2024 to 2032.

    Osteoarthritis Market Size 2023 - 2032

    Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5136

    Osteoarthritis Market Overview: Key Insights and Trends

    In 2023, knee osteoarthritis was the leading cause of wear and tear in the market, accounting for more than 49% of the total share. Imaging tests played a dominant role in diagnosing the condition, holding a significant market share. North America stood out with a substantial 38% market share in the same year. According to the Centers for Disease Control and Prevention (CDC), osteoarthritis made up 2.5% of all health issues in 2023, contributing to 20% of the overall burden of musculoskeletal conditions.

    Globally, osteoarthritis affects around 3.3% to 3.6% of people and is a major cause of disability for approximately 43 million individuals, ranking it as the 11th most disabling condition worldwide. In the United States, around 80% of people aged 65 and older show signs of osteoarthritis on X-rays, but only 60% experience symptoms. This discrepancy occurs because changes observed in X-ray images do not always directly correlate with the joint pain a person feels.

    Osteoarthritis is a common joint disorder where the cartilage that protects the bones wears down over time. This can cause pain, stiffness, and reduced flexibility in affected joints, such as the hands, hips, and knees.

    Key Factors Contributing to Osteoarthritis:

    • Age: The risk of developing osteoarthritis increases with age.
    • Sex: Women are more likely to develop osteoarthritis after the age of 50 compared to men.
    • Obesity: Excess weight puts added stress on joints, especially those that bear weight, such as the knees and hips, increasing the risk of osteoarthritis. Additionally, obesity may lead to metabolic changes that further raise the risk.
    • Genetics: A family history of osteoarthritis increases the likelihood of developing the condition.

    In 2020-21, approximately $4.3 billion was spent on osteoarthritis care, representing 2.9% of total healthcare spending and 29% of the spending on all musculoskeletal conditions.

    While osteoarthritis is not curable, proper treatment is essential to manage symptoms, improve joint function, and enhance quality of life. Treatment strategies include lifestyle changes like exercise and weight management, medications to manage pain and inflammation, and, in some cases, surgery. Early diagnosis and intervention are critical to slowing disease progression and maintaining an active lifestyle.

    Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/osteoarthritis-market-sizing

    Access exclusive insight now @ https://www.towardshealthcare.com/price/5136

    We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

    Web: https://www.towardshealthcare.com

    Visit Dental Specifics: https://www.towardsdental.com

    Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

    For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

  • Tendonitis Treatment Market Trends, Key Insights and Growth Forecast (2024 – 2032)

    Tendonitis Treatment Market Growth and Outlook (2024 – 2032)

    The global tendonitis treatment market is expected to expand significantly, growing from USD 214.26 billion in 2023 to approximately USD 298.14 billion by 2032. This growth reflects a compound annual growth rate (CAGR) of 3.6% during the forecast period from 2024 to 2032.

    Tendonitis Treatment Market Size 2023 - 2032

    Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5135

    Report Highlights:

    • In 2023, therapies accounted for 65% of the tendonitis treatment market, making them the most preferred approach.
    • Medications held a 25% market share in 2023.
    • North America led the market, capturing 42% of the share.
    • Over 70,000 Americans miss work each year due to tendonitis, according to the Bureau of Labor Statistics, with this number continuing to rise, highlighting the growing need for improved treatment options.

    Understanding Tendonitis

    Tendonitis is an inflammation of the tendons, the connective tissue between muscles and bones. Imagine your body as a well-coordinated team, where muscles and tendons work together seamlessly. In tendonitis, however, the tendons become strained, leading to pain. The condition most commonly affects the shoulders, elbows, wrists, knees, and heels.

    The Impact of Repetitive Movements

    Occupational activities involving repetitive motions and physical strain are major contributors to tendonitis. Jobs such as typing, assembly line work, and manual labor can place constant stress on specific tendons, which over time may lead to inflammation and injury. This strain increases the demand for tendonitis treatments.

    Workers in industries like construction, manufacturing, and data entry are especially vulnerable, as their daily tasks involve repetitive movements that can deplete the tendons. The growing number of individuals exposed to these risks has led to an increased need for treatments, ranging from basic rest and physical therapy to more advanced interventions.

    Preventative Measures in the Workplace

    Regular breaks are essential for recovery, as they allow the body time to heal. Short pauses during work, combined with stretching or changing positions, can help prevent muscle overuse and reduce strain on tendons. Stretching exercises, particularly those targeting areas prone to tendonitis, are beneficial, while strengthening exercises can provide better muscle support to protect the tendons.

    Employers play a key role in promoting a healthy work environment by providing ergonomic tools, conducting training on proper practices, and fostering a culture focused on employee well-being. Early intervention is crucial for preventing more serious issues—if tendonitis symptoms appear, seeking medical advice, using ice or heat therapy, and adjusting work tasks can help speed recovery.

    Recent Developments

    • In April 2022, Boehringer Ingelheim launched RenuTrend, a novel treatment for tendon and ligament injuries in horses. Administered via injection directly into the affected area, it’s the first of its kind in Europe, complementing the company’s existing stem cell treatments for horses.
    • In September 2021, Stryker introduced the Citrelock Tendon Fixation Device System, which aids in repairing damaged tendons without further injury. The system uses a specialized thread made from materials like citrate, calcium, and phosphate, which support bone healing.

    Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/tendonitis-treatment-market-sizing

    Access exclusive insight now @ https://www.towardshealthcare.com/price/5135

    We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

    Web: https://www.towardshealthcare.com

    Visit Dental Specifics: https://www.towardsdental.com

    Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

    For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

  • Cervical Spondylosis Diagnosis and Treatment Market Forecast (2024 – 2032)

    Cervical Spondylosis Diagnosis and Treatment Market Forecast (2024 – 2032)

    Cervical Spondylosis Diagnosis and Treatment Market Trends, Growth, and Forecast (2024 – 2032)

    The market for cervical spondylosis diagnosis and treatment is expected to expand significantly, growing from USD 6.21 billion in 2023 to approximately USD 11.83 billion by 2032. This growth represents a compound annual growth rate (CAGR) of 6.7% during the period from 2024 to 2032.

    Cervical Spondylosis Diagnosis and Treatment Market Size 2023 - 2032

    Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5134

    The Role of Aging in Cervical Spondylosis Development

    As we age, our bodies undergo natural changes, and one common issue that arises is the wear and tear of the bones and cartilage in the neck, known as cervical spondylosis. This condition becomes more likely with age as the bones and tissues in the neck weaken. Over time, the discs between the vertebrae in the neck may thin and lose their ability to absorb shock, leading to pain, stiffness, and discomfort.

    Cervical spondylosis is especially common in individuals aged 60 and above, with over 85% of people in this age group experiencing some form of it. As the global population ages, the demand for cervical spondylosis diagnosis and treatment is increasing. Older adults are more prone to developing the condition due to the natural aging process, which puts more stress on the spine.

    Additionally, age-related health issues like osteoporosis, which weakens the bones, can make the spine more susceptible to degeneration, worsening the symptoms of cervical spondylosis. As older adults become more vulnerable to this condition, the need for accurate diagnosis and effective treatment options rises. Healthcare providers often recommend various treatments, such as pain management, physical therapy, or even surgery, to ease symptoms and improve mobility for those affected.

    As the aging population continues to grow, the prevalence of cervical spondylosis will likely increase, driving the demand for personalized diagnosis and treatment solutions tailored to older adults’ specific needs.

    Advancements in Imaging Enhance Cervical Spondylosis Diagnosis

    Recent advancements in diagnostic imaging, such as MRI and CT scans, have significantly improved doctors’ ability to diagnose and treat cervical spondylosis. MRI uses magnets and radio waves to create detailed images of the body, while CT scans rely on X-rays to capture images from various angles.

    These imaging techniques have made it easier for doctors to detect cervical spondylosis by providing clearer pictures of the bones, discs, nerves, and soft tissues in the neck. This helps doctors pinpoint problems more accurately and develop better treatment plans for each patient. For example, they can identify nerve compression in the neck and plan treatments to relieve that pressure, which can reduce pain and improve symptoms.

    In a study conducted in April 2023 by Guangxi Normal University, China, researchers explored innovative rehabilitation therapies like Sling Exercises, fascia manipulation, Muscle Energy Technique, Proprioceptive Neuromuscular Facilitation, and virtual reality (VR) technology. The study found that combining VR technology with these therapies improved pain management for cervical spondylosis patients.

    Imaging also plays a vital role in tracking a patient’s progress over time. By comparing images taken at different stages, doctors can see how effective the treatments are and make adjustments if necessary. Thanks to MRI and CT scans, doctors now have powerful tools to diagnose and treat cervical spondylosis, ultimately helping patients manage the condition better and improve their quality of life.

    Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/cervical-spondylosis-diagnosis-and-treatment-market-sizing

    Access exclusive insight now @ https://www.towardshealthcare.com/price/5134

    We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

    Web: https://www.towardshealthcare.com

    Visit Dental Specifics: https://www.towardsdental.com

    Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

    For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare